Nanocarriers are delivery platforms of drugs, peptides, nucleic acids and other therapeutic molecules that are indicated for severe human diseases. Gliomas are the most frequent type of brain tumor, with glioblastoma being the most common and malignant type. The current state of glioma treatment requires innovative approaches that will lead to efficient and safe therapies. Advanced nanosystems and stimuli-responsive materials are available and well-studied technologies that may contribute to this effort. The present study deals with the development of functional chimeric nanocarriers composed of a phospholipid and a diblock copolymer, for the incorporation, delivery and pH-responsive release of the antiglioma agent TRAM-34 inside glioblastoma cells. Nanocarrier analysis included light scattering, protein incubation and electron microscopy, and flu-orescence anisotropy and thermal analysis techniques were also applied. Biological assays were carried out in order to evaluate the nanocarrier nanotoxicity in vitro and in vivo, as well as to evaluate antiglioma activity. The nanosystems were able to successfully manifest functional properties under pH conditions, and their biocompatibility and cellular internalization were also evident. The chimeric nanoplatforms presented herein have shown promise for biomedical applications so far and should be further studied in terms of their ability to deliver TRAM-34 and other therapeutic molecules to glioblastoma cells.

Chimeric stimuli-responsive liposomes as nanocarriers for the delivery of the anti-glioma agent TRAM-34 / Naziris, N.; Pippa, N.; Sereti, E.; Chrysostomou, V.; Kedzierska, M.; Kajdanek, J.; Ionov, M.; Milowska, K.; Balcerzak, L.; Garofalo, S.; Limatola, C.; Pispas, S.; Dimas, K.; Bryszewska, M.; Demetzos, C.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 22:12(2021), p. 6271. [10.3390/ijms22126271]

Chimeric stimuli-responsive liposomes as nanocarriers for the delivery of the anti-glioma agent TRAM-34

Garofalo S.
Methodology
;
Limatola C.
Conceptualization
;
2021

Abstract

Nanocarriers are delivery platforms of drugs, peptides, nucleic acids and other therapeutic molecules that are indicated for severe human diseases. Gliomas are the most frequent type of brain tumor, with glioblastoma being the most common and malignant type. The current state of glioma treatment requires innovative approaches that will lead to efficient and safe therapies. Advanced nanosystems and stimuli-responsive materials are available and well-studied technologies that may contribute to this effort. The present study deals with the development of functional chimeric nanocarriers composed of a phospholipid and a diblock copolymer, for the incorporation, delivery and pH-responsive release of the antiglioma agent TRAM-34 inside glioblastoma cells. Nanocarrier analysis included light scattering, protein incubation and electron microscopy, and flu-orescence anisotropy and thermal analysis techniques were also applied. Biological assays were carried out in order to evaluate the nanocarrier nanotoxicity in vitro and in vivo, as well as to evaluate antiglioma activity. The nanosystems were able to successfully manifest functional properties under pH conditions, and their biocompatibility and cellular internalization were also evident. The chimeric nanoplatforms presented herein have shown promise for biomedical applications so far and should be further studied in terms of their ability to deliver TRAM-34 and other therapeutic molecules to glioblastoma cells.
2021
Chimeric liposomes; Drug delivery; Functional; Glioblastoma; PH-responsive; TRAM-34; Apoptosis; Cell Proliferation; Drug Carriers; Glioma; Humans; Hydrogen-Ion Concentration; Liposomes; Nanoparticles; Polymers; Pyrazoles; Tumor Cells, Cultured; Drug Delivery Systems
01 Pubblicazione su rivista::01a Articolo in rivista
Chimeric stimuli-responsive liposomes as nanocarriers for the delivery of the anti-glioma agent TRAM-34 / Naziris, N.; Pippa, N.; Sereti, E.; Chrysostomou, V.; Kedzierska, M.; Kajdanek, J.; Ionov, M.; Milowska, K.; Balcerzak, L.; Garofalo, S.; Limatola, C.; Pispas, S.; Dimas, K.; Bryszewska, M.; Demetzos, C.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 22:12(2021), p. 6271. [10.3390/ijms22126271]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1571519
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact